Application: Alzheimer’s Disease Model
In vivo imaging of Amyloid beta plaque modality change treated by chemical drug in Alzheimer’s Disease Model
Abstract
In this experiment, we aimed to observe the temporal changes in Amyloid beta plaque accumulation in a 5xFAD mouse model of Alzheimer's disease by implanting Cranial Imaging Windows. The Amyloid beta plaque accumulates around the cerebral vasculature, and the focus of the study was to observe the reduction in plaque distribution in response to the drug developed from chemical compounds.
Therapeutic Target(s)
The purpose of the chemical drug treatment aimed at inhibiting Amyloid beta plaque accumulation is to address the pathology of dementia, a type of degenerative brain disease. This treatment is related to the drug's ability to penetrate the blood-brain barrier (BBB) and its response, focusing on changes associated with the accumulation of Amyloid beta plaques around cerebral blood vessels, which is a characteristic feature of the pathology occurring around the vasculature.
Mouse Model
The 5xFAD animal model, used as an Alzheimer's disease model, is a transgenic mouse that accumulates Amyloid beta plaques around cerebral blood vessels at six months of age or older. This model is generally useful for observing changes in Amyloid beta plaques in response to therapeutic agents.
Experiment Design
Group #1 - Control
- Dosing: Receive Vehicle (Drug formulation buffer) via oral administration.
- Frequency: Oral administration for 14 days
- Sample Size: N=3
Group #2 - Chemical Drug Treatment
- Dosing: Receive Chemical Drug via oral administration.
- Frequency: Oral administration for 14 days
- Sample Size: N=3
Duration
- Total Time (Initiation to Completion): 1 month (including preparation of 6-month-old 5xFAD mouse model)
